QuantSoar
HealthcareQuantSoar snapshot generated·Data source: Yahoo Finance·Market data may be delayed
BI

BIO Stock Analysis

NYQ · Healthcare · Medical Devices

$380.51

-0.48 (-0.13%)

OverviewTechnicalRiskWhaleEarningsOptionsShort InterestESG

BIO Interactive Price Chart & Trading Signals

BIO Stock Snapshot — Valuation, Risk & Technical Signals

BIO Key Fundamentals, Analyst Targets & Company Profile

Key Financial Ratios

Marktkapitalisatie

$10.17B

P/E

46.46

Forward P/E

37.65

PEG

4.01

P/B

1.42

EPS

$8.19

Dividendrendement

—

52W bereik

$236.73 – $396.23

Beta

1.07

Volume

0.0M

ROE

3.1%

Winstmarge

8.6%

Omzetgroei

-0.1%

Brutomarge

52.0%

EV/EBITDA

22.54

Analystendoel

$328.75

The trailing price-to-earnings ratio stands at 46.5x. Forward P/E of 37.6x implies earnings expansion expected. Price-to-book is 1.42x. EV/EBITDA sits at 22.54x. Market capitalization is $10.17B. Revenue is contracting at -0.1% on a trailing basis. Earnings are expanding at 18.7%. Profit margins are 8.6%. Return on equity is 3.1%. Beta of 1.07 indicates market-average volatility.

Analyst Consensus

Aanbeveling

Hold

Doel laag

$280.00

Doel gemiddeld

$328.75

Doel hoog

$390.00

Gebaseerd op 4 analisten

Over BIO

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

United States7,450 medewerkersWebsite ↗

Handel BIO op Interactive Brokers

Lagekosten wereldhandel

BIO Deep Dive Analysis

Bottom Line

Verdict

Overvalued

Best for

General investor

Watch out for

Premium valuation, Revenue contraction

Non-zero inputs

4/5

Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.

Bio-Rad Laboratories, Inc. (BIO) trades above our multi-model fair value estimate of $219.88 by approximately 42.2%. Trailing P/E: 46.5x. Profitability signals include profit margin of 8.6% and return on equity of 3.1%. Recent growth metrics show revenue growth of -0.1% and earnings growth of 18.7%. Risk profile: beta of 1.07. Consensus: hold.

Valuation, Growth & Risk

Valuation

Overvalued

P/E 46.5x

Price is above what fundamentals suggest.

Growth

Stable

Rev -0.1%

Revenue is moving sideways.

Valuation Snapshot

Bio-Rad Laboratories, Inc. (BIO) trades above our multi-model fair value estimate of $219.88 by approximately 42.2%. The trailing price-to-earnings ratio stands at 46.5x. Forward P/E of 37.6x suggests earnings compression ahead. Price-to-sales is 3.9x. Price-to-book is 1.4x. EV/EBITDA sits at 22.5x. Market capitalization is $10.17B.

Why it matters: Paying a premium works only if the company keeps growing faster than expected.

Growth & Profitability

Revenue is contracting at -0.1% on a trailing basis. Earnings are expanding at 18.7%. Profit margins are 8.6%. Return on equity is 3.1%. Return on assets is 1.7%.

Why it matters: Falling revenue can signal losing market share or industry headwinds.

Risk Profile

Beta of 1.07 indicates market-average volatility. Net debt position is $-248099968.00.

Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.

Analyst Context

Analyst consensus target of $328.75 implies 13.6% downside. Target range spans $280.00 to $390.00. 4 analysts cover the stock. Consensus recommendation: hold.

Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.

Data Methodology & Sources

Market Data (Facts)

  • Price, volume, and market cap: Yahoo Finance (may be delayed)
  • P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
  • Analyst estimates: Yahoo Finance (coverage and update times vary)
  • Insider transactions: Yahoo Finance (reporting may be delayed)

QuantSoar Model (Derived)

  • Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
  • Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
  • Composite Score: 40% Value + 30% Momentum + 30% Risk
  • Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.

Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.

BIO Overvalued

Bio-Rad Laboratories, Inc. (BIO) trades above our multi-model fair value estimate of $219.88 by approximately 42.2%.

Frequently Asked Questions

ValuationIs BIO stock overvalued right now?
Based on our discounted cash flow and relative valuation models, BIO appears to trade above fair value by approximately 42.2%. This suggests the market may be pricing in elevated growth expectations or sentiment premiums.
ValuationWhat is BIO fair value based on current fundamentals?
Our fair value estimate for BIO is $219.88, derived from discounted cash flow, dividend discount, and relative valuation multiples. The estimate assumes a discount rate of 9.0% and terminal growth of 2.5%.
RiskHow risky is BIO compared with other stocks?
Risk profile for BIO: a beta of 1.07 is near market average. Investors should weigh macro exposure against their own risk tolerance.
GrowthIs BIO still growing?
Latest trailing metrics show revenue contraction of 0.1% and earnings growth of 18.7%. Profit margins are 8.6%.
AnalystWhat do analysts think about BIO?
Analyst consensus target is $328.75, implying 13.6% downside. The street recommendation is "hold".
CatalystWhat could change the investment case for BIO?
Key catalysts include Healthcare sector dynamics, interest rate shifts, and company-specific earnings surprises. Monitor macro risk scores and analyst estimate revisions for early signals.

Related Stocks

Healthcare

Explore top stocks in this sector

Explore sector →

Stock valuation guideMacro risk explained guide
Phasakorn Traklang (Peach)

เกี่ยวกับผู้เขียน

Phasakorn Traklang (Peach) — ผู้ก่อตั้ง

ภาสกร ตรากลาง (พีช) เป็นผู้ก่อตั้ง QuantSoar และนักวิจัยการลงทุนเชิงปริมาณที่เชี่ยวชาญด้านการประเมินมูลค่าหุ้นหลายโมเดล การวิเคราะห์กระแสสถาบัน และการสร้างพอร์ตแบบเป็นระบบ เขาสร้างแพลตฟอร์มการเงินที่ขับเคลื่อนด้วยข้อมูลเพื่อให้บริการนักลงทุนรายย่อยทั่วโลก

เชื่อมต่อ LinkedIn

Investment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC

Gegevens: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub